Back

Invigorating human MSCs for transplantation therapy via Nrf2/DKK1 co- stimulation in a mice acute-on-chronic liver failure model

Chen, F.; Che, Z.; Liu, Y.; Luo, P.; Xiao, L.; Song, Y.; Wang, C.; Dong, Z.; Li, M.; Tipoe, G. L.; Wu, D.; Yang, M.; Lv, Y.; Wang, F.; Wang, H.; Xiao, J.

2022-05-30 molecular biology
10.1101/2022.05.29.493908 bioRxiv
Show abstract

Boosting stem cell resilience against an extrinsically harsh recipient environment is critical to therapeutic efficiency of stem cell-based transplantation innovations in liver disease contexts. We aimed to establish the efficacy of a transient plasmid-based preconditioning strategy to boost mesenchymal stromal cells (MSCs) capacity for anti-inflammation/antioxidant defense and paracrine actions on recipient hepatocytes. In MSCs, the master antioxidant regulator Nrf2 was found to bind directly to the antioxidant response element in the DKK1 promoter region. Activation of Nrf2 and DKK1 enhanced the anti-stress capacities of MSCs in vitro. In an acute-on-chronic liver failure (ACLF) murine model, transient co-overexpression of Nrf2 and DKK1 via plasmid transfection markedly improved MSC resilience against inflammatory and oxidative assaults, boosted MSC transplantation efficacy and promoted recipient liver regeneration because of a shift from the activation of the anti-regenerative IFN-{gamma}/STAT1 pathway to the pro-regenerative IL-6/STAT3 pathway in the liver. Moreover, specific ablation of DKK1 receptor CKAP4 but not LRP6 in recipient hepatocytes nullified therapeutic benefits from MSC transplantation. In long-term observations, tumorigenicity was undetected in mice following transplantation of such transiently preconditioned MCSs. In conclusion, co-stimulation of Nrf2/DKK1 signaling decisively and safely improves the efficacy of human MSC-based therapies in mouse ACLF models through apparently CKAP4-dependent paracrine mechanisms.

Matching journals

The top 10 journals account for 50% of the predicted probability mass.

1
Stem Cell Research & Therapy
30 papers in training set
Top 0.1%
18.8%
2
Cell Death & Disease
126 papers in training set
Top 0.1%
6.4%
3
International Journal of Molecular Sciences
453 papers in training set
Top 1%
4.9%
4
Biomedicine & Pharmacotherapy
43 papers in training set
Top 0.1%
4.0%
5
eLife
5422 papers in training set
Top 25%
3.6%
6
Advanced Science
249 papers in training set
Top 6%
3.1%
7
Frontiers in Cell and Developmental Biology
218 papers in training set
Top 3%
2.4%
8
Nature Communications
4913 papers in training set
Top 45%
2.4%
9
PLOS ONE
4510 papers in training set
Top 46%
2.4%
10
Molecular Therapy
71 papers in training set
Top 1%
2.1%
50% of probability mass above
11
Cell Discovery
54 papers in training set
Top 2%
2.1%
12
Stem Cells
28 papers in training set
Top 0.2%
1.9%
13
Scientific Reports
3102 papers in training set
Top 58%
1.7%
14
Protein & Cell
25 papers in training set
Top 1%
1.7%
15
Cells
232 papers in training set
Top 3%
1.7%
16
Hepatology Communications
21 papers in training set
Top 0.3%
1.3%
17
Stem Cell Reports
118 papers in training set
Top 0.6%
1.3%
18
Journal of Hepatology
18 papers in training set
Top 0.2%
1.3%
19
The Journal of Heart and Lung Transplantation
10 papers in training set
Top 0.2%
1.2%
20
Acta Biochimica et Biophysica Sinica
19 papers in training set
Top 0.5%
1.2%
21
Cell Death Discovery
51 papers in training set
Top 0.8%
1.2%
22
Journal of Translational Medicine
46 papers in training set
Top 2%
1.1%
23
Molecular Therapy - Nucleic Acids
24 papers in training set
Top 0.2%
1.1%
24
Acta Pharmaceutica Sinica B
11 papers in training set
Top 0.7%
1.0%
25
Biomedicines
66 papers in training set
Top 3%
0.8%
26
Journal of Molecular Cell Biology
21 papers in training set
Top 0.7%
0.8%
27
Frontiers in Immunology
586 papers in training set
Top 8%
0.8%
28
Clinical and Translational Medicine
30 papers in training set
Top 1%
0.7%
29
Cell Research
49 papers in training set
Top 3%
0.6%
30
Hepatology
18 papers in training set
Top 0.4%
0.6%